Citadel Advisors
UBX

Citadel Advisors’s Unity Biotechnology UBX Stock Holding History

Citadel Advisors’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-69,210
Closed -$102K – 15421
2024
Q3 		$102K Sell
69,210
-2,998
-4% -$4.4K ﹤0.01% 11089
2024
Q2 		$97.5K Sell
72,208
-21,383
-23% -$32.5K ﹤0.01% 10951
2024
Q1 		$153K Buy
93,591
+44,915
+92% +$77.9K ﹤0.01% 10735
2023
Q4 		$93.9K Buy
+48,676
New +$90.5K ﹤0.01% 11005
2023
Q3 		– Sell
-1,673
Closed -$4.43K – 15145
2023
Q2 		$4.27K Sell
1,673
-920
-35% -$2.43K ﹤0.01% 13613
2023
Q1 		$4.23K Sell
2,593
-31,527
-92% -$126K ﹤0.01% 13974
2022
Q4 		$93.5K Buy
34,120
+22,787
+201% +$66.2K ﹤0.01% 11320
2022
Q3 		$45K Buy
11,333
+2,267
+25% +$14.3K ﹤0.01% 11707
2022
Q2 		$51K Buy
9,066
+3,207
+55% +$26.8K ﹤0.01% 11934
2022
Q1 		$66K Sell
5,859
-4,123
-41% -$46.3K ﹤0.01% 12616
2021
Q4 		$146K Buy
9,982
+7,728
+343% +$169K ﹤0.01% 12297
2021
Q3 		$67K Sell
2,254
-2,966
-57% -$105K ﹤0.01% 13187
2021
Q2 		$242K Sell
5,220
-5,217
-50% -$251K ﹤0.01% 11771
2021
Q1 		$627K Buy
10,437
+5,644
+118% +$385K ﹤0.01% 9191
2020
Q4 		$251K Buy
4,793
+1,330
+38% +$64.1K ﹤0.01% 9388
2020
Q3 		$120K Sell
3,463
-10,485
-75% -$664K ﹤0.01% 9164
2020
Q2 		$1.21M Sell
13,948
-5,574
-29% -$413K ﹤0.01% 5475
2020
Q1 		$1.13M Sell
19,522
-17,139
-47% -$1.08M ﹤0.01% 5110
2019
Q4 		$2.64M Sell
36,661
-526
-1% -$37.1K ﹤0.01% 3982
2019
Q3 		$2.27M Buy
37,187
+13,348
+56% +$944K ﹤0.01% 4276
2019
Q2 		$2.27M Buy
23,839
+19,497
+449% +$1.66M ﹤0.01% 4300
2019
Q1 		$352K Buy
+4,342
New +$492K ﹤0.01% 7374
2018
Q3 		– Sell
-1,522
Closed -$230K – 9704
2018
Q2 		$230K Buy
+1,522
New +$222K ﹤0.01% 7647

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Citadel Advisors's UBX Position: Q4 2024 in Review

Citadel Advisors sold out of Unity Biotechnology (UBX) in Q4 2024, closing a stake of 69,210 shares — an estimated $102K sold.

Citadel Advisors first reported a position in UBX in Q2 2018 and held it in 23 quarters. The position peaked at $2.64M in Q4 2019. 37 funds tracked by Wall St. Rank hold UBX as of Q4 2024.

  • Citadel Advisors reported no remaining Unity Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 69,210 Unity Biotechnology shares in Q4 2024, an estimated $102K.
  • Citadel Advisors first reported a position in Unity Biotechnology in Q2 2018 and held it in 23 quarters.
  • Citadel Advisors's Unity Biotechnology position peaked at $2.64M in Q4 2019.
  • 37 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.